Autolus appoints Robert Azelby to Board, commercial focus as BLA for obe-cel submitted

Autolus Therapeutics plc

Robert W. Azelby appointed Class II director effective Jan 9, 2024; brings 30+ years biopharma commercial experience.
Initial option grant of 80,000 ADSs at $6.84/share; annual retainer £52,500 plus £3,500 for committee service.
Azelby was CEO of Eliem Therapeutics and Alder BioPharmaceuticals; served at Juno and Amgen.
Company recently submitted BLA for lead CAR T therapy obe-cel; Azelby to aid commercialization.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert W. Azelby

Class II director

AUTL · Autolus Therapeutics plc

Effective: 2024-01-09
Filed: January 10, 2024, 6:59 PM ET

appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert W. Azelby was appointed as Class II director at Autolus Therapeutics plc.

Action: appointed
Role: Class II director

Exact text from the filing

appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.

View on SEC.gov

Autolus Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001730463-24-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.